Gleevec All Financial Data in US $ (mln)

Word Search (Top 10 - by date)

Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors
Tocagen (May 05, 2015)
Novartis Delivered Sales Growth (cc), Significant Margin Expansion (cc) and Strong Innovation in Q1[1]; Now with a More Focused Portfolio
Novartis (April 23, 2015)
Kite Pharma Commends Honors Conferred to Drs. Owen Witte and Steven A. Rosenberg at the 2015 American Association for Cancer Research (AACR) Annual Meeting
Kite Pharma (April 21, 2015)
Hybrigenics Presents New in Vitro Results on Inecalcitol in Chronic Myeloid Leukemia at the AACR Meeting in Philadelphia, USA
Hybrigenics (April 20, 2015)
Caris Life Sciences Vice Chairman Dr. Jonathan Knowles to Receive Personalized Medicine World Conference UK 2015 Luminary Award
Caris Life Sciences (April 13, 2015)
Novartis Delivered Solid Sales Growth, Margin Expansion and Pipeline Progress in 2014
Novartis (January 27, 2015)
Professor Shiloh, Israel Cancer Research Fund "Research Professor" Awarded First Olav Thon Foundation Prize
Cancer Genetics (January 22, 2015)
Hybrigenics Launches Phase II Clinical Study of Inecalcitol in Chronic Myeloid Leukemia
Hybrigenics (January 19, 2015)
Raze Therapeutics Announces Addition of Julian Adams, PhD, George Q. Daley, MD, PhD, and Karen Vousden, PhD, to Scientific Advisory Board
Raze Therapeutics (January 07, 2015)
The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan (December 10, 2014)

Displaying 10 out of a possible 610 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Gleevec
Generic Name:   imatinib mesylate
Therapeutic Subcategory:     Other cytostatics

Product Sales Summary 2012/13

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic Name Therapeutic Subcategory 2012 2013 2013
Gleevec2 4,675 4,693 +0%
Note: Shaded Cells3

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Gleevec4 639


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product:5 Gleevec

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now